Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes

  • Authors:
    • Minoru Tomizawa
    • Yuji Kawanabe
    • Fuminobu Shinozaki
    • Sumihiko Sato
    • Yasufumi Motoyoshi
    • Takao Sugiyama
    • Shigenori Yamamoto
    • Makoto Sueishi
  • View Affiliations

  • Published online on: July 1, 2014     https://doi.org/10.3892/br.2014.309
  • Pages: 633-636
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to reveal the metabolic disorders most commonly associated with nonalcoholic fatty liver disease (NAFLD). Triglyceride (TG), high‑density lipoprotein cholesterol (HDL), low‑density lipoprotein cholesterol (LDL), blood glucose (BG) and hemoglobin A1c (HbA1c) were analyzed. NAFLD was diagnosed using abdominal ultrasound (US), and TG, HDL, LDL, BG and HbA1c were immediately collected on the same day and subjected to multivariate regression analysis. Stepwise analysis was performed to select the variables that were closely associated with NAFLD. The patients who were positive for the hepatitis B antigen and hepatitis C antibody were excluded from the study. Additionally, the patients who were prescribed prednisolone or methotrexate were excluded from the study as these agents may cause NAFLD or liver toxicity. The study included 168 and 125 patients with and without NAFLD, respectively. TG, BG and HbA1c were strongly correlated with NAFLD. Among these parameters, TG was the strongest predictor of NAFLD (χ2=9.89, P=0.0017). TG was the parameter that was most strongly associated with NAFLD. In conclusion, elevated TG was a marker of NAFLD.

References

1 

Chalasani N, Younossi Z, Lavine JE, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55:2005–2023. 2012. View Article : Google Scholar

2 

Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 129:113–121. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Dunn W, Xu R, Wingard DL, et al: Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 103:2263–2271. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Chatrath H, Vuppalanchi R and Chalasani N: Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 32:22–29. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Musso G, Gambino R, Cassader M and Pagano G: Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 43:617–649. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Festi D, Schiumerini R, Marzi L, et al: Review article: the diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods. Aliment Pharmacol Ther. 37:392–400. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Miyake T, Kumagi T, Hirooka M, et al: Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol. 48:413–422. 2013. View Article : Google Scholar

9 

Promrat K, Kleiner DE, Niemeier HM, et al: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 51:121–129. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Abe N, Honda S and Jahng D: Evaluation of waist circumference cut-off values as a marker for fatty liver among Japanese workers. Saf Health Work. 3:287–293. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Rafiq N, Bai C, Fang Y, et al: Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 7:234–238. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Eguchi Y, Hyogo H, Ono M, et al: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 47:586–595. 2012. View Article : Google Scholar

13 

Haukeland JW, Konopski Z, Eggesbo HB, et al: Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 44:853–860. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Vernon G, Baranova A and Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Nelson A, Torres DM, Morgan AE, Fincke C and Harrison SA: A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol. 43:990–994. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Alvarez F, Berg PA, Bianchi FB, et al: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 31:929–938. 1999. View Article : Google Scholar : PubMed/NCBI

17 

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV and Heathcote EJ; American Associaiton for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 50:291–308. 2009. View Article : Google Scholar

18 

Matsumoto T, Yamasaki S, Arakawa A, et al: Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. Pathol Int. 57:388–389. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA and Kelly TN: Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis. 18:359–367. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 123:1705–1725. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Nakahara T, Hyogo H, Yoneda M, et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. Nov 26–2013.(Epub ahead of print).

23 

Ma H, Xu C, Xu L, Yu C, Miao M and Li Y: Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol. 13:32013. View Article : Google Scholar : PubMed/NCBI

24 

Sung KC, Kim BS, Cho YK, et al: Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC Gastroenterol. 12:842012. View Article : Google Scholar : PubMed/NCBI

25 

Lottenberg AM, Afonso Mda S, Lavrador MS, Machado RM and Nakandakare ER: The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem. 23:1027–1040. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Wiernsperger N: Hepatic function and the cardiometabolic syndrome. Diabetes Metab Syndr Obes. 6:379–388. 2013. View Article : Google Scholar

Related Articles

Journal Cover

September 2014
Volume 2 Issue 5

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tomizawa, M., Kawanabe, Y., Shinozaki, F., Sato, S., Motoyoshi, Y., Sugiyama, T. ... Sueishi, M. (2014). Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomedical Reports, 2, 633-636. https://doi.org/10.3892/br.2014.309
MLA
Tomizawa, M., Kawanabe, Y., Shinozaki, F., Sato, S., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., Sueishi, M."Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes". Biomedical Reports 2.5 (2014): 633-636.
Chicago
Tomizawa, M., Kawanabe, Y., Shinozaki, F., Sato, S., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., Sueishi, M."Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes". Biomedical Reports 2, no. 5 (2014): 633-636. https://doi.org/10.3892/br.2014.309